Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species
ERCC1 and XPF (show ERCC4 ELISA Kits) protect short telomeres from homologous recombination.
we quantified the frequency of aneuploidy of three autosomes in the cerebral cortex and cerebellum of adult and developing brain of Bub1b (show BUB1B ELISA Kits)(H/H) mice, which have a faulty mitotic checkpoint (show BUB3 ELISA Kits), and Ercc1(-/Delta7) mice, defective in nucleotide excision repair and inter-strand crosslink repair. we found that Bub1b (show BUB1B ELISA Kits)(H/H), but not Ercc1(-/Delta7) mice, have a significantly higher frequency of aneuploid nuclei relative to wild-t...
these results establish USP45 as a new regulator of XPF (show ERCC4 ELISA Kits)-ERCC1 crucial for efficient DNA repair
ERCC1 is critical for protecting chondrocytes from catabolic stress and is associated with the pathophysiology of osteoarthritis.
SLX4 (show BTBD12 ELISA Kits) is a tumor suppressor, which activates XPF (show ERCC4 ELISA Kits)-ERCC1 nuclease (show DCLRE1C ELISA Kits) specificity in DNA crosslink repair.
ERCC1 is essential for melanoma growth and resistance to cisplatin.
Smad4 (show SMAD4 ELISA Kits) loss-associated Snail (show SNAI1 ELISA Kits) reduction compromises Ercc1-mediated DNA repair, contributing to increased UV-induced skin carcinogenesis.
analysis of accelerated loss of hearing and vision in the DNA-repair deficient Ercc1(delta/-) mouse
This study demonistrated that the ERCC1 deficiency-associated downregulation of the cholesterol biosynthesis pathway is at least in part due to lowered expression of its master transcription factor SREBF2 (show SREBF2 ELISA Kits)
we have identified a novel skin-specific Ercc1 transcript in mice that originates from a promoter approximately 400 bp upstream of the normal promoter, rather than from more distant potential transcriptional start sites.
Ercc1(Delta/-) mice develop widespread astrocytosis and microgliosis, and motor neuron loss and denervation of skeletal muscle fibers.
Immunohistochemical expression of ERCC1 and XRCC1 (show XRCC1 ELISA Kits) has some predictive and prognostic values in patients with biliary tract cancer. Nuclear expression of ERCC1 and XRCC1 (show XRCC1 ELISA Kits) may be used to predict therapeutic response in patients undergoing gemcitabine monotherapy.
ERCC1 rs3212986 gene polymorphism has a significant effect on the pharmacokinetics and treatment outcome of gastric cancer. No association was found between ERCC1 rs11615 and overall survival of gastric cancer.
study finds that ERCC1 and RRM1 (show RRM1 ELISA Kits) are not independent prognostic factors of recurrence in stage I non-small cell lung cancer patients
High ERCC1 expression is associated with poor Response to Platinum-Based Induction Chemotherapy in Head and Neck Cancer.
ERCC1 rs11615 (C>T) polymorphism was associated with therapeutic response in Caucasian patients and C allele of ERCC1 rs11615 could represent a genetic molecular marker to predict better patient response to radiochemotherapy (meta-analysis).
Our results indicated that the ERCC1 codon 118 polymorphism may have predictive potential for chemotherapy treatment responses in late-stage bladder cancer patients
The prognostic index comprising XRCC1 (show XRCC1 ELISA Kits) rs25487, ERCC2 (show ERCC2 ELISA Kits) rs13181, and rs1799793 polymorphisms may be a useful predictor of clinical outcomes in MGC treated with EOF.
It was concluded that patients with stage I NSCLC with high ERCC1 expression had superior survival rates relative to those with low ERCC1 expression. Tumors with an irregular edge and signs of spiculation on CT were significantly correlated with low expression of ERCC1.
Stratified analyses revealed that A/A + G/A genotypes of XRCC1 (show XRCC1 ELISA Kits) rs25487 are associated with significantly reduced risk of death compared with the G/G genotype in patients grouped by tumor size, portal vein tumor thrombus (PVTT), alpha-fetoprotein (AFP (show AFP ELISA Kits)) and TNM (show ODZ1 ELISA Kits) stage (all p < 0.05). The ERCC1 rs13181 and XPD (show ERCC2 ELISA Kits) rs11615 polymorphisms were not predictive of clinical outcome for HCC (show FAM126A ELISA Kits) patients
ERCC1 Gene C8092A Polymorphism is associated with response to Platinum-based Chemotherapy in Advanced Gastric Cancer.
The product of this gene functions in the nucleotide excision repair pathway, and is required for the repair of DNA lesions such as those induced by UV light or formed by electrophilic compounds including cisplatin. The encoded protein forms a heterodimer with the XPF endonuclease (also known as ERCC4), and the heterodimeric endonuclease catalyzes the 5' incision in the process of excising the DNA lesion. The heterodimeric endonuclease is also involved in recombinational DNA repair and in the repair of inter-strand crosslinks. Mutations in this gene result in cerebrooculofacioskeletal syndrome, and polymorphisms that alter expression of this gene may play a role in carcinogenesis. Multiple transcript variants encoding different isoforms have been found for this gene. The last exon of this gene overlaps with the CD3e molecule, epsilon associated protein gene on the opposite strand.
DNA excision repair protein ERCC-1
, excision repair cross-complementing 1
, excision repair 1